Spectrum seeks rapid approval for anticancer contender

Spectrum Pharmaceuticals ($SPPI) hit the main efficacy goal of a midstage study of its drug belinostat for treating patients with certain cases of peripheral T-Cell lymphoma. And the company plans to advance the program, which has fast-track status in the U.S., to an FDA review next year. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.